Evidence map›Paper›PMID 20015075›Full record

ArticleThe FEBS journal2010

Aegyptin displays high-affinity for the von Willebrand factor binding site (RGQOGVMGF) in collagen and inhibits carotid thrombus formation in vivo.

Eric Calvo, Fuyuki Tokumasu, Daniella M Mizurini, Peter McPhie, David L Narum, José Marcos C Ribeiro, Robson Q Monteiro, Ivo M B Francischetti

Open access · bronzeAbstract read
In one paragraph

Article in The FEBS journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Collagen-binding protein, Aegyptin, regulates probing time and blood feeding success in the dengue vector mosquito, Aedes aegypti.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Eric CalvoSection of Vector Biology, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases/NIH, Bethesda, MD 20852, USA.
Fuyuki Tokumasu
Daniella M Mizurini
Peter McPhie
David L Narum
José Marcos C Ribeiro
Robson Q Monteiro
Ivo M B Francischetti
National Institute of Allergy and Infectious Diseases · USUniversidade Federal do Rio de Janeiro · BRVector (United States) · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

Vector-Borne Diseases: Biology Of Vector Host RelationshipZIAAI000810 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RIBEIRO, JOSE · 2009 to 2025
$20.8M
Biochemical And Biophysical ParasitologyZIAAI000099 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WELLEMS, THOMAS E · 2009 to 2014
$1.8M
Thermodynamic and kinetic studies of protein structure and enzymic mechanismsZIADK024964 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI WICKNER, REED B. · 2009 to 2016
$1.8M
Intramural NIH HHS Z99 AI999999
6 · The paper itself

Abstract

Aegyptin is a 30 kDa mosquito salivary gland protein that binds to collagen and inhibits platelet aggregation. We have studied the biophysical properties of aegyptin and its mechanism of action. Light-scattering plot showed that aegyptin has an elongated monomeric form, which explains the apparent molecular mass of 110 kDa estimated by gel-filtration chromatography. Surface plasmon resonance identified the sequence RGQOGVMGF (where O is hydroxyproline) that mediates collagen interaction with von Willebrand factor (vWF) as a high-affinity binding site for aegyptin, with a K(D) of approximately 5 nM. Additionally, aegyptin interacts with the linear peptide RGQPGVMGF and heat-denatured collagen, indicating that the triple helix and hydroxyproline are not a prerequisite for binding. However, aegyptin does not interact with scrambled RGQPGVMGF peptide. Aegyptin also recognizes the peptides (GPO)(10) and GFOGER with low affinity (microM range), which respectively represent glycoprotein VI and integrin alpha2beta1 binding sites in collagen. Truncated forms of aegyptin were engineered, and the C-terminus fragment was shown to interact with collagen and to attenuate platelet aggregation. In addition, aegyptin prevents laser-induced carotid thrombus formation in the presence of Rose Bengal in vivo, without significant bleeding in rats. In conclusion, aegyptin interacts with distinct binding sites in collagen, and is useful tool to inhibit platelet-collagen interaction in vitro and in vivo.

Indexed as

AedesAmino Acid SequenceAnimalsBase SequenceBinding SitesBiophysical PhenomenaCarotid Artery ThrombosisCollagenDNA, ComplementaryFemaleFibrinolytic AgentsHydroxyprolineInsect ProteinsIntegrin alpha2beta1In Vitro TechniquesKineticsCollagenDNA, ComplementaryFibrinolytic AgentsHydroxyprolineInsect ProteinsIntegrin alpha2beta1Peptide FragmentsPlatelet Membrane Glycoproteinsplatelet membrane glycoprotein VISalivary Proteins and Peptidesvon Willebrand Factor

Identifiers

PMID20015075
PMCPMC2892622
OpenAlexW1900862155

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.